These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 35288040)

  • 41. Prevalence of hypoglycemia among a sample of sulfonylurea-treated patients with Type 2 diabetes mellitus in Argentina: The real-life effectiveness and care patterns of diabetes management (RECAP-DM) study.
    Gonzalez C; Monti C; Pinzon A; Monsanto H; Ejzykowicz F;
    Endocrinol Diabetes Nutr (Engl Ed); 2018 Dec; 65(10):592-602. PubMed ID: 30076124
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A Cross-Sectional study on risk factors for severe hypoglycemia among Insulin-Treated elderly type 2 diabetes Mellitus (T2DM) patients in Singapore.
    Shi Min Ko M; Kit Lee W; Chang Ang L; Goh SY; Mong Bee Y; Ming Teh M
    Diabetes Res Clin Pract; 2022 Mar; 185():109236. PubMed ID: 35131380
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Reduced Hypoglycemia Risk in Type 2 Diabetes Patients Switched to/Initiating Insulin Glargine 300 vs 100 U/ml: A European Real-World Study.
    Escalada J; Bonnet F; Wu J; Bonnemaire M; Gupta S; Cambron-Mellott JM; Nicholls C; Müller-Wieland D
    Adv Ther; 2020 Sep; 37(9):3863-3877. PubMed ID: 32681460
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
    Hollander P; Cooper J; Bregnhøj J; Pedersen CB
    Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Characteristics of Patients with Type-1 or Type-2 Diabetes Receiving Insulin Glargine U300: An Analysis of 7268 Patients Based on the DPV and DIVE Registries.
    van Mark G; Lanzinger S; Sziegoleit S; Putz FJ; Durmaz M; Borscheller M; Danne T; Seufert J; Holl RW; Bramlage P
    Adv Ther; 2019 Jul; 36(7):1628-1641. PubMed ID: 31119688
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hypoglycemia in patients with type 2 diabetes treated with oral antihyperglycemic agents detected by continuous glucose monitoring: a multi-center prospective observational study in Croatia.
    Baretić M; Bralić Lang V
    BMC Endocr Disord; 2020 Mar; 20(1):35. PubMed ID: 32151247
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and Cardiovascular Safety of Linagliptin as an Add-On to Insulin in Type 2 Diabetes: A Pooled Comprehensive Post Hoc Analysis.
    Zinman B; Ahrén B; Neubacher D; Patel S; Woerle HJ; Johansen OE
    Can J Diabetes; 2016 Feb; 40(1):50-7. PubMed ID: 26474870
    [TBL] [Abstract][Full Text] [Related]  

  • 48. High incidence of hypoglycemia in stable insulin-treated type 2 diabetes mellitus: continuous glucose monitoring vs. self-monitored blood glucose. Observational prospective study.
    Pazos-Couselo M; García-López JM; González-Rodríguez M; Gude F; Mayán-Santos JM; Rodríguez-Segade S; Rodríguez-García J; Casanueva F
    Can J Diabetes; 2015 Oct; 39(5):428-33. PubMed ID: 26254702
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Continuous Glucose Monitoring-Recorded Hypoglycemia with Insulin Degludec or Insulin Glargine U100 in People with Type 1 Diabetes Prone to Nocturnal Severe Hypoglycemia.
    Brøsen JMB; Agesen RM; Alibegovic AC; Ullits Andersen H; Beck-Nielsen H; Gustenhoff P; Krarup Hansen T; Hedetoft CGR; Jensen TJ; Stolberg CR; Bogh Juhl C; Lerche SS; Nørgaard K; Parving HH; Tarnow L; Thorsteinsson B; Pedersen-Bjergaard U
    Diabetes Technol Ther; 2022 Sep; 24(9):643-654. PubMed ID: 35467938
    [No Abstract]   [Full Text] [Related]  

  • 50. The psychosocial and financial impact of non-severe hypoglycemic events on people with diabetes: two international surveys.
    Fulcher G; Singer J; Castañeda R; Fraige Filho F; Maffei L; Snyman J; Brod M
    J Med Econ; 2014 Oct; 17(10):751-61. PubMed ID: 25061766
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The science of hypoglycemia in patients with diabetes.
    Oyer DS
    Curr Diabetes Rev; 2013 May; 9(3):195-208. PubMed ID: 23506375
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and safety of generic exenatide injection in Chinese patients with type 2 diabetes: a multicenter, randomized, controlled, non-inferiority trial.
    Yang J; Xiao W; Guo L; Li Q; Zhong L; Yang J; Yang J; Gao Y; Tian Q; Hong T
    Acta Diabetol; 2020 Aug; 57(8):991-1000. PubMed ID: 32206903
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of diabetes duration on hypoglycaemia in patients with type 2 diabetes treated with insulin glargine or NPH insulin.
    Dailey GE; Gao L; Aurand L; Garg SK
    Diabetes Obes Metab; 2013 Dec; 15(12):1085-92. PubMed ID: 23683002
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A comprehensive risk assessment for nocturnal hypoglycemia in geriatric patients with type 2 diabetes: A single-center case-control study.
    Kanazawa K; Suzuki S; Koga S; Kuwabara K
    J Diabetes Complications; 2022 Aug; 36(8):108239. PubMed ID: 35810146
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Conversations and Reactions Around Severe Hypoglycemia Study: Results of Hypoglycemia Experiences in Canadian Adults With Insulin-Treated Diabetes and Their Caregivers.
    Mojdami D; Mitchell BD; Spaepen E; Syring K; Rabasa-Lhoret R; Punthakee Z; Snoek F; Peyrot M
    Can J Diabetes; 2021 Apr; 45(3):236-242. PubMed ID: 33087294
    [TBL] [Abstract][Full Text] [Related]  

  • 56. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2).
    Yki-Järvinen H; Bergenstal R; Ziemen M; Wardecki M; Muehlen-Bartmer I; Boelle E; Riddle MC;
    Diabetes Care; 2014 Dec; 37(12):3235-43. PubMed ID: 25193531
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Risk of hypoglycemia following intensification of metformin treatment with insulin versus sulfonylurea.
    Roumie CL; Min JY; Greevy RA; Grijalva CG; Hung AM; Liu X; Elasy T; Griffin MR
    CMAJ; 2016 Apr; 188(6):E104-E112. PubMed ID: 26811361
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Association of Insulin Pump Therapy vs Insulin Injection Therapy With Severe Hypoglycemia, Ketoacidosis, and Glycemic Control Among Children, Adolescents, and Young Adults With Type 1 Diabetes.
    Karges B; Schwandt A; Heidtmann B; Kordonouri O; Binder E; Schierloh U; Boettcher C; Kapellen T; Rosenbauer J; Holl RW
    JAMA; 2017 Oct; 318(14):1358-1366. PubMed ID: 29049584
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Case Series of U-500 Insulin Use in Adults With Type 2 Diabetes and Severe Insulin Resistance.
    Zamora JM; Kong JM
    Can J Diabetes; 2021 Feb; 45(1):55-58. PubMed ID: 32847768
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Incidence of severe hypoglycemia and its association with serum adiponectin in Japanese patients with type 1 and insulin-treated type 2 diabetes: The Fukuoka Diabetes Registry.
    Iwase M; Komorita Y; Fujii H; Ohkuma T; Ide H; Yoshinari M; Oku Y; Higashi T; Nakamura U; Kitazono T
    J Diabetes Investig; 2020 Sep; 11(5):1258-1264. PubMed ID: 32180356
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.